 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| 12345678910111213...1920» |
- || Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Review, Journal: Prospects of anti-GD2 immunotherapy for retinoblastoma. (Pubmed Central) - Dec 2, 2024
Additionally, chimeric antigen receptors (CAR)-T therapy, GD2 vaccines and nanoparticles are also potential therapeutics. Finally, we discuss the prospects and current limitations of these immunotherapeutic approaches for treating retinoblastoma, as well as how to address these problems.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal: Molecular Interactions of the Plant Steroid Hormone Epibrassinolide on Human Drug-Sensitive and Drug-Resistant Small-Cell Lung Carcinoma Cells. (Pubmed Central) - Nov 27, 2024
Pharmacologic interactions between EB and the Wnt signaling inhibitors IGC-011 and PRI-724 were determined by the combination index method and showed antagonism, indicating that EB acts on the same pathway as these inhibitors...Following exposure to human liver microsomes, EB was metabolized by NADPH-dependent oxidation and UDPG-dependent glucuronidation, as evidenced by the elimination of EB cytotoxicity against SCLC cells. Taken together, these data indicate that EB, a steroid hormone in plants consumed in the human diet, is pharmacologically active in drug-sensitive and drug-resistant SCLC cells in the Wnt signaling pathway, alters apoptotic gene expression, and is a substrate for microsomal modifications.
- || Amnolake (tamibarotene) / Syros
PK/PD data, Journal: Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors. (Pubmed Central) - Nov 26, 2024
In the final model, the body surface area was included as a covariate for apparent total body clearance, the central compartment volume of distribution, and the peripheral compartment volume of distribution. Visual prediction checks and bootstrap analysis confirmed the validity and predictive accuracy of the final model as satisfactory.
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma, magrolimab (ONO-7913) / Ono Pharma
Enrollment change, Trial completion date: Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma (clinicaltrials.gov) - Nov 26, 2024
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Visual prediction checks and bootstrap analysis confirmed the validity and predictive accuracy of the final model as satisfactory. N=82 --> 12 | Trial completion date: Sep 2024 --> Nov 2025
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal, IO biomarker: Exploiting potential molecular compounds for treating testicular seminoma by targeting immune related genes. (Pubmed Central) - Nov 22, 2024
The signature initially constructed based on immune-related genes shows promise for predicting outcomes and assessing the efficacy of immunotherapy in seminoma patients. Rutin, ICG-001, and Doxorubicin have demonstrated potential to target these signature genes and inhibit tumor cell viability.
- | Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial primary completion date: MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - Nov 18, 2024
P1, N=45, Active, not recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Rutin, ICG-001, and Doxorubicin have demonstrated potential to target these signature genes and inhibit tumor cell viability. Trial primary completion date: Jun 2023 --> Feb 2024
- || nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Review, Journal: The role of CD98 heavy chain in cancer development. (Pubmed Central) - Nov 16, 2024
Targeting CD98hc/LAT1, alone or with conventional therapies, shows promise in inhibiting tumor growth. This review focuses on elucidating the multifaceted roles of CD98hc and its partner LAT1 in cancer, particularly its involvement in amino acid transport, signaling pathways, and its prognostic relevance in cancer.
- | Journal: An integrated bioinformatics approach to early diagnosis, prognosis and therapeutics of non-small-cell lung cancer. (Pubmed Central) - Nov 14, 2024
The stability of three top-ranked drug-target interactions (CAV1 vs. ZSTK474, CAV1 vs. GSK2126458, and ASPM vs. Trametinib) were investigated by computing their binding free energies for 140 ns MD-simulation based on MM-PBSA approach. Therefore, the findings of this computational study may be useful for early prognosis, diagnosis and therapies of NSCLC.
- eprenetapopt (APR-246) / Aprea
APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5212;
In our work, APR-246/Erwinase combination effectively disrupts the balance between ROS generation and antioxidation dependent on glutamine/GSH metabolism in ASNase-R cells and leads to cell death by ferroptosis. Prospective phase I/II studies are now required to confirm the clinical efficacy of APR-246/Erwinase combination in ASNase-R ENKTL and ALL patients.
- Novel Promising Therapeutic Strategies for Advancing the Treatment of KMT2A-Rearranged AML (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_2713;
We support the use of pediatric AML-PDXs in preclinical testing for their ability to mimic the heterogeneity of drug response, aiding in the identification of tailored second-line treatments. VEN+ASPN combination represents a novel promising therapeutic strategy for advancing the treatment of KMT2A-rearranged AML.
- Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_2610;
In contrast to prior observation, the presence of Abs did not predict ASPA inactivation. Pts who switched to ERW during LI had a higher risk of relapse, possibly due the different pharmacology profile between both asparaginases.
- Amnolake (tamibarotene) / Syros
Abundance of Relapse-Predictive Cells Can be Estimated at Diagnosis and Is Strongly Associated with Outcome in Pediatric AML (Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)) - Nov 6, 2024 - Abstract #ASH2024ASH_1322;
Patient-derived xenograft (PDX) models were treated with cytarabine (50 mg/kg/dose) or saline on days 1-4...The RARA/RXRA complex represses transcription in the absence of retinoic acid; transcription can be activated by the agonist tamibarotene (tami)...We validated the association of these cell types with chemoresistance in PDX models. We identified retinoic acid receptor agonism as a potential strategy to deplete one of these cell types.
- ||| Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open, Combination therapy: NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (clinicaltrials.gov) - Nov 6, 2024
P2, N=62, Recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
We identified retinoic acid receptor agonism as a potential strategy to deplete one of these cell types. Not yet recruiting --> Recruiting
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Trial primary completion date: NANT 2013-01: Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells (clinicaltrials.gov) - Nov 5, 2024
P1, N=13, Active, not recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Not yet recruiting --> Recruiting Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
- Danyelza (naxitamab) - Y / mAbs Therap
Budget Impact and Cost-Utility Analysis of Naxitamab Plus GM-CSF for the Treatment of Refractory/Relapsed HR-NB in the Brazilian Private Healthcare Population () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1844;
To demonstrate the economic impact of incorporating the immunotherapy options Naxitamab plus GM-CSF and Beta-dinutuximab for the treatment of refractory/relapsed HR-NB in the private health system of Brazil. Naxitamab plus GM-CSF demonstrated to be a cost-saving and cost-effective option compared to Betadinutuximab for the treatment of refractory/relapsed HR-NB within the private health system in Brazil.
- A Value Framework Based on Multiple Criteria Decision Analysis for New Health Technologies Assessment Under Universal Healthcare Coverage System in Taiwan () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1209;
A country-specific value framework based on MCDA for new drugs was developed in an Asian setting under universal healthcare coverage. It allows multiple stakeholders to systematically appraise all drug value attributes and provides a structured process for adapting and refining value assessments.
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Trial suspension, Trial primary completion date: Rapid Administration Pilot for Infusing Dinutuximab (clinicaltrials.gov) - Nov 1, 2024
P4, N=11, Suspended, Sponsor: Children's Hospital Los Angeles
It allows multiple stakeholders to systematically appraise all drug value attributes and provides a structured process for adapting and refining value assessments. Trial completion date: Aug 2024 --> Jun 2025 | Recruiting --> Suspended | Trial primary completion date: Aug 2024 --> Jun 2025
- | OP-11 / Ohara Pharma
Journal: ZSTK474 targeting PIK3R3 inhibits the Wilms' tumor through G0 / G1 phase arrest. (Pubmed Central) - Oct 28, 2024
Trial completion date: Aug 2024 --> Jun 2025 | Recruiting --> Suspended | Trial primary completion date: Aug 2024 --> Jun 2025 This research provides insight into the potential of ZSTK474 and other PI3K inhibitors for treating nephroblastoma.
- | Amnolake (tamibarotene) / Syros
Journal: Development of the esterase PestE for amide bond synthesis under aqueous conditions: Enzyme cascades for converting waste PET into tamibarotene. (Pubmed Central) - Oct 28, 2024
Rational mutagenesis led to identification of PestE variants F33L_F289A and F33L. F33L_F289A increased conversion of N-benzylfuranamide by 1.2-fold, and F33L gave a 4-fold increase in conversion to tamibarotene.
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Combination therapy: ANBL19P1: Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Oct 22, 2024
P2, N=41, Active, not recruiting, Sponsor: Children's Oncology Group
F33L_F289A increased conversion of N-benzylfuranamide by 1.2-fold, and F33L gave a 4-fold increase in conversion to tamibarotene. Trial completion date: Sep 2024 --> Sep 2025
- | nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Journal: JPH203 alleviates peritoneal fibrosis via inhibition of amino acid-mediated mTORC1 signaling. (Pubmed Central) - Oct 19, 2024
Trial completion date: Sep 2024 --> Sep 2025 JPH203 alleviates PF by inhibiting amino acid-mediated mTORC1 signaling.
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date: NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Oct 17, 2024
P2, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
JPH203 alleviates PF by inhibiting amino acid-mediated mTORC1 signaling. Trial completion date: Sep 2024 --> Sep 2025
- foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
AN ORAL INHIBITOR OF CBP/?-CATENIN SIGNALING, C-82, IMPROVES LIVER STEATOSIS, FUNCTION, INFLAMMATION AND FIBROSIS IN THE GAN DIET-INDUCED OBESE MOUSE MODEL OF MASH () - Oct 15, 2024 - Abstract #AASLD2024AASLD_777;
C-82 treatment improves not only MASH-like liver disorders (steatosis, function and inflammation) but also liver fibrosis. C-82, an oral inhibitor of CBP/?-catenin signaling, shows a potent therapeutic effect on MASH-related liver fibrosis and steatosis.
- revumenib (SNDX-5613) / Syndax Pharma, Amnolake (tamibarotene) / Syros
Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation (Shanghai) - Oct 13, 2024 - Abstract #DGHO2024DGHO_1415;
The effect of the menin inhibitor revumenib in KMT2Ar or NPM1c AML cells is significantly improved by the combination with tamibarotene. Both pronounced induction of differentiation or rapid induction of apoptosis by revumenib and tamibarotene represent promising strategies for patients with molecularly defined relapsed or refractory AML.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Anti-CD40 monoclonal antibody combined with a current anti-GD2 chemo-immunotherapy regimen can eradicate 9464D-GD2 neuroblastoma in mice (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_598;
Conclusions These results indicate that addition of aCD40 can improve the efficacy of TIG treatment in a high-risk NBL tumor model. Further testing with combinatory treatments is underway in efforts to produce similar results against larger tumors.Download figure Open in new tab Download powerpoint Abstract 707 Figure 1
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Journal: Local Sustained Dinutuximab Delivery and Release From Methacrylated Chondroitin Sulfate. (Pubmed Central) - Oct 3, 2024
The CSMA hydrogel-only treatment slowed tumor growth as well, an interesting effect that may indicate interactions between the CSMA and cell adhesion molecules in the tumor microenvironment. These findings demonstrate a potential avenue for local sustained delivery of dinutuximab for improved anti-tumoral response in high-risk NB.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
SURVIVAL OUTCOMES IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA (HRNB) RECEIVING EFLORNITHINE (DFMO) MAINTENANCE TREATMENT WITH MATCHED EXTERNAL CONTROLS: SUBGROUP ANALYSIS ON GEOGRAPHIC REGION () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1488;
This post hoc analysis confirms that DFMO-treated patients with HNRB in remission after standard upfront therapy have better outcomes than matched control patients even when considering geographic region. Overall, these data further support DFMO as a maintenance treatment for HRNB.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
BRIDGING THE GAP: ADVANCED PRACTICE NURSE LED INITIATIVE TO STREAMLINE SUPPORTIVE CARE ORDERS FOR DINUTUXIMAB ADMINISTRATION IN THE INPATIENT SETTING () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1263;
Overall, these data further support DFMO as a maintenance treatment for HRNB. Through shared expertise in anti-GD2 immunotherapy administration, APNs were instrumental in developing an orderset that guided the workflow for safe and efficient dinutuximab administration in the inpatient setting.
- Keytruda (pembrolizumab) / Merck (MSD)
CHARACTERIZING THE FEASIBILITY AND SAFETY OF PEMBROLIZUMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN THE TREATMENT OF RELAPSED/REFRACTORY NEUROBLASTOMA () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1157;
The addition of pembrolizumab to neuroblastoma chemoimmunotherapy regimens was feasible for our patients, without significant increase in Grade 3 AE's. The use of checkpoint inhibitors warrants further prospective investigation.
- tozasertib (MK-0457) / Merck (MSD), Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
TARGETED ANTI-CANCER DRUG DELIVERY IN NEUROBLASTOMA () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1090;
The cytotoxic effect of DTX-?/EVER-TOZA@PEG-b-PLGA in cells significantly reduced tumor sizes in mice. Our in vitro and in vivo animal model findings support the potential of DTX-?/EVER-TOZA@PEG-b-PLGA combination as a candidate in vivo therapeutic agent for NB.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
PAIN RESPONSE TO CHEMOIMMUNOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY NEUROBLASTOMA () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1053;
Dintuximab-related pain is well tolerated with supportive care and the majority of treatment days had a MPS of 0. There is evidence of decreasing pain and opiate use over the course of therapy.
- Danyelza (naxitamab) - Y / mAbs Therap
EXTENDED NAXITAMAB THERAPY IN REFRACTORY/RELAPSED (R/R) HIGH-RISK NEUROBLASTOMA (HR-NB): A MULTI-CENTER, RETROSPECTIVE CASE SERIES () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1027;
Extended outpatient naxitamab therapy (8-20 cycles) was associated with sustained remission or maintained disease control in heavily pretreated patients with R/R HR-NB. Given the high risk of further relapse, patient/caregivers often requested extended treatment, which was feasible without evidence of unanticipated or cumulative toxicity.
- ketamine / Generic mfg.
NURSING COLLABORATION SUPPORTING OUTPATIENT KETAMINE ADMINISTRATION FOR PEDIATRIC ANTI-GD2 IMMUNOTHERAPY () - Oct 2, 2024 - Abstract #SIOP2024SIOP_974;
Effective collaboration amongst a multidisciplinary team fosters the possibility of innovative treatment strategies. Teamwork and creativity are key when managing side effects of therapies critical in the treatment of pediatric cancers and malignancies.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Intraoperative Molecular Imaging of Neuroblastoma with DTPA[In-111]-Dinutuximab-IR800: Optimization to Prepare for Clinical Use (Hyatt Regency Orlando, Windermere Ballroom W) - Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_1453;
Furthermore, the tracer enabled tumor visualization in vivo with the commonly used SPY-PHI intraoperative NIRC. Thus, lower F/Ab enables adequate binding and accumulation while minimizing background signal.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Evaluation of Indocyanine Green-Labeled Dinutuximab as a Novel Intraoperative Molecular Imaging Agent for Neuroblastoma: An Orthotopic Murine Model (Hyatt Regency Orlando, Windermere Ballroom W) - Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_1427;
ICG-D specifically targets and fluoresces in vivo neuroblastoma xenograft tumors. Future studies aim to optimize the antibody protein-ICG ratio and evaluate the utility of ICG-D for recurrent metastatic disease.
- Danyelza (naxitamab) - Y / mAbs Therap, humanised dinutuximab (Hu14.18K322A) / Essential Pharma, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Survival Outcomes in Children with High-Risk Neuroblastoma Treated with Anti-GD2 Immunotherapy: A Single-Arm Systematic Review and Meta-Analysis (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) - Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_1190;
Of these, 11 studies evaluated Dinutuximab, three studies evaluated Naxitamab, two studies hu14.18K322A, and two studies 3F8. This single-arm meta-analysis suggests that high-risk Neuroblastoma patients may benefit from anti-GD2 immunotherapy, with promising impacts on OS, PFS, and EFS.
- | nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Journal: Endothelial specific LAT1 ablation normalizes tumor vasculature. (Pubmed Central) - Sep 24, 2024
lyase (CTH) induction. Increased production of hydrogen sulfide (H2S) by CTH was at least partially responsible for tumor vascular normalization, leading to decreased leakiness and enhanced delivery of chemotherapeutic agents to the tumor.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal, Metastases: Transferrin receptor-targeted immunostimulant for photodynamic immunotherapy against metastatic tumors through ?-catenin/CREB interruption. (Pubmed Central) - Sep 23, 2024
Increased production of hydrogen sulfide (H2S) by CTH was at least partially responsible for tumor vascular normalization, leading to decreased leakiness and enhanced delivery of chemotherapeutic agents to the tumor. To synthesize PTI, the photosensitizer
- foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma, GSK2816126 / GSK
SALL1 Is Essential for Histone H3K27 Methyltransferase EZH2 to Regulate Apoptotic Responses in Kidney Ischemia-Reperfusion Injury (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_2420;
Our results indicate that silencing EZH2 can protect renal function by relieving transcriptional inhibition of SALL1, activating the Wnt/?-catenin pathway, and attenuating tubular epithelial apoptosis response. These results highlight the potential therapeutic value of targeting EZH2 in ischemia/reperfusion-induced AKI.
- || nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Clinical, P2 data, Journal, Metastases: Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy. (Pubmed Central) - Sep 15, 2024
Compared with placebo, nanvuranlat improved PFS in patients with advanced and refractory BTC with an acceptable safety profile. Further studies of this promising compound are warranted in the population of patients who are exhausted from treatment options.
- | nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Journal: LAT1 supports mitotic progression through Golgi unlinking in an amino acid transport activity-independent manner. (Pubmed Central) - Sep 14, 2024
Unexpectedly, JPH203, an inhibitor of LAT1 amino acid transport activity, does not affect mitotic progression...These results suggest that LAT1 supports mitotic progression in an amino acid transport activity-independent manner and that Golgi-localized LAT1 is important for mitotic progression through the acceleration of Golgi unlinking and centrosome maturation. These findings reveal a novel LAT1 function in mitosis.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal: Escherichia coli infection induces ferroptosis in bovine mammary epithelial cells by activating the Wnt/?-catenin pathway-mediated mitophagy. (Pubmed Central) - Sep 11, 2024
Moreover, E. coli infection activated the Wnt/?-catenin pathway, but foscenvivint alleviated it. In conclusion, E. coli infection induced ferroptosis through activation of the Wnt/?-catenin pathway-promoted mitophagy, and it also suppressed GPX4 expression.
- | Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date: MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - Sep 4, 2024
P1, N=45, Active, not recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
In conclusion, E. coli infection induced ferroptosis through activation of the Wnt/?-catenin pathway-promoted mitophagy, and it also suppressed GPX4 expression. Trial completion date: Jun 2024 --> Jun 2025
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma, Imbruvica (ibrutinib) / AbbVie, J&J
Journal: Combined targeting of Hedgehog/GLI1 and Wnt/?-catenin pathways in mantle cell lymphoma. (Pubmed Central) - Sep 1, 2024
Overall, the combined targeting of both the Hh/GLI1 and Wnt/?-catenin pathways was more effective in suppressing proliferation, inducing G0/G1 cycle retardation, promoting apoptosis, and increasing drug sensitivity of MCL cells than mono treatments. These findings emphasize the potential of combinatorial therapy for treating MCL patients.
- || Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Review, Journal: Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma. (Pubmed Central) - Aug 31, 2024
Over the past two decades, application of dinutuximab, an anti-GD2 monoclonal antibody (mAb), has been one of the few new therapies to substantially improve outcomes to current levels...Herein, we summarize the current state of the art in NBL therapeutic options and highlight the unique challenges posed by NBL that have limited the successful adoption of immune-modifying therapies. Through this review, we aim to direct the field's attention to opportunities that may benefit from a combination immunotherapy strategy.
- Venclexta (venetoclax) / Roche, AbbVie, Amnolake (tamibarotene) / Syros
SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_416;
P2
The combination was well tolerated with no new safety signals or increased myelosuppression compared with ven-aza. Data from a future prespecified interim analysis including at least 50% enrollment will be presented.
- | Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
Trial withdrawal: A Phase 1, Single Centre, Open Label, Single Dose, Pharmacokinetic Study of Erwinaze in Healthy Adult Volunteers (EUDRACT) - Aug 30, 2024
P1, N=12, Withdrawn, Sponsor: Porton Biopharma Limited
Data from a future prespecified interim analysis including at least 50% enrollment will be presented. Not yet recruiting --> Withdrawn
- || Amnolake (tamibarotene) / Syros
Enrollment closed, Combination therapy: SELECT-AML-1: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML (clinicaltrials.gov) - Aug 15, 2024
P2, N=95, Active, not recruiting, Sponsor: Syros Pharmaceuticals
Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal: PFDA promotes cancer metastasis through macrophage M2 polarization mediated by Wnt/?-catenin signaling. (Pubmed Central) - Aug 8, 2024
Furthermore, in vivo studies corroborated that PFDA-pretreated RAW264.7 could promote tumor metastasis, which could be mitigated by pretreatment with the ?-catenin inhibitor ICG001. In conclusion, our study demonstrated that PFDA could promote cancer metastasis through regulating macrophage M2 polarization in a Wnt/?-catenin-dependent manner.
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Journal: Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. (Pubmed Central) - Aug 7, 2024
Despite EBRT, LRR remains a contributor to treatment failure in HR-NBL with approximately half of LRRs including a component of marginal failure. Future prospective studies are needed to explore whether radiation fields and doses should be defined based on molecular features such as MYCN amplification, and/or response to chemotherapy.